Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

2082.7000 0.80 (0.04%)

NSE Dec 02, 2025 15:31 PM

Volume: 1.2M

Lupin Ltd.

09 Nov 2024

2082.70

0.04%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.